Catherine A Vlastaris, MD | |
33100 Cleveland Clinic Blvd - Avw3-2, Cleveland Clinic Richard E Jacobs Health Center, Avon, OH 44011 | |
(440) 695-4000 | |
(440) 695-4389 |
Full Name | Catherine A Vlastaris |
---|---|
Gender | Female |
Speciality | Dermatology |
Experience | 32 Years |
Location | 33100 Cleveland Clinic Blvd - Avw3-2, Avon, Ohio |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407803042 | NPI | - | NPPES |
2091525 | Medicaid | OH | |
070017531 | Other | OH | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | 35064822 (Ohio) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Cleveland Clinic | Cleveland, OH | Hospital |
Cleveland Clinic Avon Hospital | Avon, OH | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
While the U.S. has made great progress in the prevention and treatment of tuberculosis, the nation has become more susceptible to potential epidemics of multidrug-resistant tuberculosis (MDR-TB), according a study led by Johns Hopkins researchers. Computer simulations show that as TB prevalence falls, the risk for more extensive MDR-TB increases.
A sluggish economy, changing government regulation and court cases have prompted new business strategies at hospitals, according to news reports.
Experts say it is too early to assess if an international initiative, Roll Back Malaria (RBM), has had any impact on combating malaria.
Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).
› Verified 6 days ago
Entity Name | The Cleveland Clinic Foundation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
While the U.S. has made great progress in the prevention and treatment of tuberculosis, the nation has become more susceptible to potential epidemics of multidrug-resistant tuberculosis (MDR-TB), according a study led by Johns Hopkins researchers. Computer simulations show that as TB prevalence falls, the risk for more extensive MDR-TB increases.
A sluggish economy, changing government regulation and court cases have prompted new business strategies at hospitals, according to news reports.
Experts say it is too early to assess if an international initiative, Roll Back Malaria (RBM), has had any impact on combating malaria.
Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Catherine A Vlastaris, MD 33100 Cleveland Clinic Blvd - Avw3-2, Cleveland Clinic Richard E Jacobs Health Center, Avon, OH 44011 Ph: (440) 695-4000 | Catherine A Vlastaris, MD 33100 Cleveland Clinic Blvd - Avw3-2, Cleveland Clinic Richard E Jacobs Health Center, Avon, OH 44011 Ph: (440) 695-4000 |
News Archive
While the U.S. has made great progress in the prevention and treatment of tuberculosis, the nation has become more susceptible to potential epidemics of multidrug-resistant tuberculosis (MDR-TB), according a study led by Johns Hopkins researchers. Computer simulations show that as TB prevalence falls, the risk for more extensive MDR-TB increases.
A sluggish economy, changing government regulation and court cases have prompted new business strategies at hospitals, according to news reports.
Experts say it is too early to assess if an international initiative, Roll Back Malaria (RBM), has had any impact on combating malaria.
Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).
› Verified 6 days ago
Dr. Cynthia Lavery Henry, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2535 Hale St, Suite A, Avon, OH 44011 Phone: 440-934-8810 Fax: 440-934-8811 |